Sanofi has announced the construction of a new EUR 1.3 billion ($1.4 billion) insulin production facility at its BioCampus in Frankfurt Höchst, Germany.  

By 2029, several hundred employees are expected to work in the new plant, which covers an area of approximately 36,000 square meters. The new plant will replace existing insulin production plants and also have renewable energy sources.  

The Sanofi BioCampus in Frankfurt is one of the company’s largest integrated manufacturing and distribution sites. The site is involved in the value chain of many of Sanofi’s medicines, including insulins and a growing number of immunology biologics. It covers the entire insulin production chain, from active ingredient production to the manufacture of cartridges and ampoules, the assembly of pens and auto-injectors, and global distribution. The Sanofi BioCampus currently supplies 80 countries with 20 different insulin products. 

Source: Sanofi